. 2012 Aug;37(8):453-454, 456-463.

Table 1.

Summary of Primary Endpoints for TAX 327 and Southwest Oncology Group (SWOG) 9916 Trials

Trial	Treatment Group	Death Rate (%)	HR for Survival (95% CI)	Median Survival Duration (Months)

TAX 327^a	• Docetaxel 75 mg/m² every 3 weeks	50.0	0.76 (0.62–0.94)	18.9 (17.0–21.2)^*
	• Docetaxel 30 mg/m² every week	57.0	0.91 (0.75–1.11)	17.4 (15.7–19.0)^*
	• Mitoxantrone 12 mg/m² every 3 weeks	60.0	Reference	16.5 (14.4–18.6)^*

SWOG 9916^b	• Docetaxel 60–70 mg/m² estramustine 280 mg, and dexamethasone 60 mg every 3 weeks	64.0	0.80 (0.67–0.97)	17.5
	• Mitoxantrone 12–14 mg/m² and prednisone 5 mg every 3 weeks	70.0	Reference	15.6

95% confidence interval.

Data from Tannock IF, de Wit R, Berry WR et al. N Engl J Med 2004;351(15):1502–1512.³⁰

Data from Petrylak DP, Tangen CM, Hussain MH, et al. N Engl J Med 2004;351(15):1513–1520.²⁸